Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Kelley, Robin KateRobin KateKelleyUeno, MakotoMakotoUenoYoo, ChanghoonChanghoonYooFinn, Richard SRichard SFinnFuruse, JunjiJunjiFuruseRen, ZhenggangZhenggangRenYau, ThomasThomasYauKlümpen, Heinz-JosefHeinz-JosefKlümpenChan, Stephen LStephen LChanOzaka, MasatoMasatoOzakaVerslype, ChrisChrisVerslypeBouattour, MohamedMohamedBouattourPark, Joon OhJoon OhParkBarajas, OlgaOlgaBarajasPelzer, UweUwePelzerValle, Juan WJuan WValleYu, LiLiYuMalhotra, UshaUshaMalhotraSiegel, Abby BAbby BSiegelEdeline, JulienJulienEdelineVogel, ArndtArndtVogelCHIUN HSU2024-01-092024-01-092023-06-0301406736https://scholars.lib.ntu.edu.tw/handle/123456789/638302Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract cancer is chemotherapy with gemcitabine and cisplatin. Because most biliary tract cancers have an immune-suppressed microenvironment, immune checkpoint inhibitor monotherapy is associated with a low objective response rate. We aimed to assess whether adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin would improve outcomes compared with gemcitabine and cisplatin alone in patients with advanced biliary tract cancer.enPembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialjournal article10.1016/S0140-6736(23)00727-4370757812-s2.0-85153757808https://api.elsevier.com/content/abstract/scopus_id/85153757808